Biota and Boehringer Ingelheim Complete Licence for HCV Program
In another recent deal, Biota, an Australian company has entered into a deal with Boehringer Ingelheim to develop and commercialize Biota’s nucleoside analogues for treatment of Hepatitis C.
PharmaLive: Biota and Boehringer Ingelheim Complete US$102 Million Licence for HCV Program :
The deals is worth $102 million to Biota based on meeting certain milestones. Biota would be responsible for discovery research and Boehring Ingelheim would be responsible for development and commercialization.
Hepatitis C virus(HCV) is a long standing target for many companies and one that hasn’t paid off yet. Although there are a couple of treatments for it, they are biotech products that require weekly injections. The hunt for a oral drug has not yet been successful. I remember work being done on this at Bristol-Myers Squibb way back in 1994. It would indeed be a major step forward since HCV infects approx. 170 million people and an additional 3-4 million are newly infected each year. Of these, approx. 4.1 million are in the US and of these 3.2 million are chronic.
Other Sources
Hepatitis C: Fact Sheet | CDC Viral Hepatitis
Technorati Tags: Biota, Boehringer Ingelheim, Hepatitis C
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
